FDA تمنح دواء Perjeta موافقة لاستطباب ثاني لسرطان الثدي وهوالعلاج قبل الجراحة وكانهذا الدواء حصل في 2012 على الاستطباب الاول في علاج سرطان الثدي الباكر FDA approves Perjeta for neoadjuvant breast cancer treatment First drug approved for use in preoperative breast cancer The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer. Perjeta was approved in 2012 for the treatment of patients with advanced or late-stage (metastatic) HER2-positive breast cancer. HER2-positive breast cancers have increased amounts of the HER2 protein that contributes to cancer cell growth and survival. fda.gov/newsevents/newsroom/pressannouncements/ucm370393.htm#.Ukw6vueJaeA.facebook
Posted on: Wed, 02 Oct 2013 19:45:37 +0000